Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16%
Q1 2025 highlights
LEO Pharma's revenue increased by 10% year-on-year to DKK 3,373 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (+45% at CER), with Europe (+2% at CER) and Rest of World (+5% at CER) also contributing to the overall growth.
Dermatology portfolio revenue grew by 10% (CER) year-on-year, driven by the Strategic brands, Adtralza®/Adbry® and Anzupgo®, which together saw a revenue increase of 73% (CER). Sales in the Thrombosis portfolio declined by 1% (CER) year-on-year, negatively impacted by order timing.
Operating profit improved significantly, with adjusted EBITDA reaching DKK 545 million in Q1 2025, reflecting a margin of 16% (Q1 2024: 8%) excluding the upfront payment from Gilead and other non-recurring items.
Net profit for the quarter was DKK 1,742 million (Q1 2024: negative DKK 366 million), including non-recurring items.
Free cash flow was positive DKK 1,386 million for Q1 2025 (Q1 2024: negative DKK 571 million), and net interest-bearing debt was reduced to DKK 9,750 million (YE 2024: DKK 11,115 million). Excluding one off M&A-related payments, free cash flow in Q1 2025 was negative DKK 241 million.
In Q1, LEO Pharma reported positive results from the DELTA TEEN and DELTA China trials, marking the fifth and sixth consecutive successful phase 3 trials for delgocitinib (brand name: Anzupgo®) in chronic hand ezcema. Additionally, in January, LEO Pharma announced a strategic partnership with Gilead Sciences to accelerate the pre-clinical STAT6 program.
The 2025 financial outlook for revenue growth of 6-9% (CER) and an adjusted EBITDA margin of 15-18% is unchanged and confirmed.
"We have seen a good start to 2025, with encouraging progress in the ongoing launch of Anzupgo® and key milestones achieved for our innovation pipeline. A significant highlight is the acceleration of the STAT6 program through our new partnership with Gilead. Additionally, the return to a positive net result marks another key milestone for the quarter, as we continue to develop the foundations for LEO Pharma's long-term financial strength,' says Christophe Bourdon, CEO of LEO Pharma.
Q1 2025 Financial overview
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
GES Investors Have the Opportunity to Join Investigation of Guess?, Inc. with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Guess?, Inc. ('Guess' or 'the Company') (NYSE: GES) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Guess board breached its fiduciary duties to shareholders. Guess has signed an agreement to be taken private by Authentic Brands in an all-cash deal for $16.75 per share, totaling about $1.4 billion. If you are a shareholder, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
23 minutes ago
- Business Wire
Altamira Welcomes Cassie Kurtz as Vice President of Operations
MCLEAN, Va.--(BUSINESS WIRE)--Altamira Technologies is pleased to announce the addition of Cassie Kurtz as the Vice President for the Defense Scientific and Intelligence (Defense S&TI) business in Dayton, OH. She brings nearly 25 years of leadership experience across defense intelligence, ISR modernization, and enterprise program delivery. A mission-first executive, Cassie has led large-scale portfolios, complex contract transitions, and high-tempo global teams across the U.S., Europe, and the Pacific. She is known for scaling organizations, modernizing intelligence operations, and ensuring 24/7 mission continuity. Prior to joining Altamira, Cassie spent nearly two decades at Booz Allen Hamilton, most recently leading European Intelligence programs from the United Kingdom. She also directed Army Intelligence programs across the Pacific and CONUS and was key in ISR modernization initiatives at the National Air & Space Intelligence Center (NASIC), where she stood up capabilities still in operation today. She is a USAF veteran who served as a Senior Operations Intelligence Analyst and holds degrees in Resource Management and Communications Applications Technology. Jane Chappell, CEO of Altamira Technologies shared: 'I am thrilled with the addition of Cassie Kurtz as our new Defense S&TI Vice President. Her exceptional leadership and deep expertise in ISR and advanced defense technologies will be invaluable as we continue to innovate and deliver cutting-edge solutions to our mission customers.' Cassie added: 'It's rare to find an opportunity that brings mission, leadership, and regional roots together so clearly. I'm excited to join a team that's so deeply invested in its people and the clients we serve—and to return to where my passion for the Intelligence mission first took root.'
Business Wire
23 minutes ago
- Business Wire
Dream Office REIT Announces August 2025 Monthly Distribution
TORONTO--(BUSINESS WIRE)-- DREAM OFFICE REIT (TSX: ('Dream Office' or the 'Trust') today announced its August 2025 monthly distribution of 8.333 cents ($1.00 annualized) per REIT Unit, Series A ('REIT A Units'). The August distribution will be payable on September 15, 2025 to unitholders of record as at August 29, 2025. Dream Office REIT is an unincorporated, open-ended real estate investment trust. Dream Office REIT is a premier office landlord in downtown Toronto with over 4.0 million square feet owned and managed. We have carefully curated an investment portfolio of high-quality assets in irreplaceable locations in one of the finest office markets in the world. For more information, please visit our website at
